BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fibrodysplasia Ossificans Progressiva readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Fibrodysplasia Ossifi
 cans Progressiva\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06508021-6058@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:Andecaliximab: Phase 2/3 readout est. (NCT06508021)
DESCRIPTION:Andecaliximab\, phase 2/3\, Fibrodysplasia Ossificans Progressi
 va.\nStudy: A Study of Andecaliximab in Participants With Fibrodysplasia O
 ssificans Progressiva (FOP)\nEstimated primary completion: 4 February 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/andecaliximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06508021
URL:https://assetmemo.bio/drug/andecaliximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559513-145@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20300708
DTEND;VALUE=DATE:20300709
SUMMARY:Pasatru (garetosmab): Phase 3 readout est. (NCT07559513)
DESCRIPTION:Pasatru (garetosmab)\, phase 3\, Fibrodysplasia Ossificans Prog
 ressiva.\nStudy: A Study to Investigate the Safety\, Pharmacokinetics (PK)
 \, and Efficacy of Garetosmab in Children and Adolescents With Fibrodyspla
 sia Ossificans Progressiva (FOP)\nEstimated primary completion: 8 July 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/garetosmab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07559513
URL:https://assetmemo.bio/drug/garetosmab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
